| 产品描述： | FH535 is an inhibitor of Wnt/β-catenin and PPAR, with anti-tumor activities. |
| 靶点： |
PPAR;β-catenin;Wnt/beta-catenin;PPAR |
| 体内研究： |
FH535 (25 mg/kg, i.p.) exhibits an anti-tumor effect on pancreatic cancer xenografts in mice. FH535 also represses angiogenesis in pancreatic cancer xenografts |
| 参考文献： |
1. Handeli S, et al. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther. 2008 Mar;7(3):521-9. 2. Wu MY, et al. FH535 inhibited metastasis and growth of pancreatic cancer cells. Onco Targets Ther. 2015 Jul 6;8:1651-70.3. Liu L, et al. FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. Oncotarget. 2016 Jul 26;7(30):47145-47162. |
| 溶解性： |
DMSO : 33.33 mg/mL (92.28 mM; Need ultrasonic) |
| 保存条件： |
-20℃ |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.769 ml |
13.843 ml |
27.685 ml |
| 5 mM |
0.554 ml |
2.769 ml |
5.537 ml |
| 10 mM |
0.277 ml |
1.384 ml |
2.769 ml |
| 50 mM |
0.055 ml |
0.277 ml |
0.554 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京